# US 6,348,198 B1 · Lactoferrin receptor protein > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,348,198 B1 - Document ID: US6348198B1 - Status: Granted - Kind: B1 - Application number: 09/371,127 - Filed: 1999-08-10 - Granted: 2002-02-19 - Earliest claimed: 1995-11-02 - Assignees: Aventis Pasteur Limited - Inventors: Anthony B. Schryvers; Robert A. Bonnah - Web page: https://patentgrep.com/patent/US6348198B1 ## CPC - C07K 14/22: from Neisseriaceae (F) - A61P 31/04: Antibacterial agents - C07K 14/212: {Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter} - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract An isolated and purified lactoferrin receptor protein is isolated and purified from bacterial pathogens, including Moraxella and Neisseria, and has a molecular weight of between about 70,000 and about 90,000, as determined by SDS-PAGE. Such lactoferrin receptor protein may be provided in combination with a lactoferrin receptor protein from the bacterial pathogen of a molecular weight of about 100,000 to about 105,000 daltons. The lactoferrin receptor protein may be produced by providing a solubilized membrane preparation from the bacterial pathogen containing lactoferrin receptor proteins, non-lactoferrin receptor proteins and other contaminants, complexing the lactoferrin receptor proteins with lactoferrin and purifying the resulting complexes substantially free from the non-lactoferrin receptor proteins and the other contaminants, and separating the novel lactoferrin receptor protein from the complexes. The lactoferrin receptor protein is useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the lactoferrin receptor protein or produces a protein capable of inducing antibodies in a host specifically reactive with the lactoferrin receptor protein. ## Claims ### Claim 1 An immunogenic composition, comprising a lactoferrin receptor protein having a molecular weight of between about 70,000 and about 90,000 daltons, wherein said molecular weights are determined by SDS-PAGE and wherein said lactoferrin receptor protein is isolated and purified from a bacterial pathogen selected from the group consisting of Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis, Moraxella bovis and Moraxella lacunata, and a pharmaceutically-acceptable carrier therefor. ### Claim 2 (depends on 1) The immunogenic composition of claim 1 formulated as a vaccine for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight between about 70,000 and about 90,000 daltons, as determined by SDS-PAGE or that produces a protein that induces antibodies in the host specifically reactive with the lactoferrin receptor protein. ### Claim 3 (depends on 1) The immunogenic composition of claim 1 further comprising at least one other immunogenic or immunostimulating material. ### Claim 4 (depends on 3) The immunogenic composition of claim 3 wherein the at least one other immunostimulating material is at least one adjuvant. ### Claim 5 (depends on 4) The immunogenic composition of claim 4 wherein the at least one adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, QS21, Quil A or derivatives or components thereof, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, a lipoprotein, polyphosphazene, ISCOM matrix, ISCOPREP, DC-chol and DDBA. ### Claim 6 (depends on 5) The immunogenic composition of claim 5 wherein the host is a primate. ### Claim 7 (depends on 6) The immunogenic composition of claim 6 wherein the primate is a human. ### Claim 8 (depends on 1) The immunogenic composition of claim 1 which is substantially free from transferrin receptor proteins of said pathogen. ### Claim 9 (depends on 1) A method of generating an immune response in a host, comprising administering thereto an immuno-effective amount of the immunogenic composition of claim 1. ### Claim 10 (depends on 9) The method of claim 9 wherein the immune response is a humoral or a cell-mediated immune response. ### Claim 11 (depends on 10) The method of claim 10 wherein the immune response provides protection to the host against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight of between about 70,000 and about 90,000 daltons wherein said molecular weight is determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis or that produces a protein that induces antibodies in the host specifically reactive with the lactoferrin receptor protein. ### Claim 12 (depends on 1) A method for producing a vaccine, comprising: administering the immunogenic composition of claim 1 to a test host to determine an amount and a frequency of administration thereof to confer protection against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight of between about 70,000 and about 90,000 daltons wherein said molecular weight is determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis or a protein that induces antibodies in a host specifically reactive with the lactoferrin receptor protein; and formulating the immunogenic composition in a form suitable for administration to a treated host in accordance with said determined amount and frequency of administration. ### Claim 13 (depends on 12) The method of claim 12 wherein the treated host is a human. ### Claim 14 An immunogenic composition, comprising a first lactoferrin receptor protein having a molecular weight of about 100,000 to about 105,000 daltons and a second lactoferrin receptor protein having a molecular weight of between about 70,000 and 90,000 daltons, wherein said molecular weights are determined by SDS-PAGE and wherein said lactoferrin receptor proteins are isolated and purified from a bacterial pathogen selected from the group consisting of Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis, Moraxella bovis and Moraxella lacunata. ### Claim 15 (depends on 14) The immunogenic composition of claim 14 formulated as a vaccine for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight between about 70,000 and about 90,000 daltons, as determined by SDS-PAGE or that produces a protein that induces antibodies in the host specifically reactive with the lactoferrin receptor protein. ### Claim 16 (depends on 15) The immunogenic composition of claim 15 further comprising at least one other immunogenic or immunostimulating material. ### Claim 17 (depends on 16) The immunogenic composition of claim 16 wherein the at least one other immunostimulating material is at least one adjuvant. ### Claim 18 (depends on 17) The immunogenic composition of claim 17 wherein the at least one adjuvant is selected from the group consisting of aluminum phosphate, aluminum hydroxide, QS21, Quil A or derivatives or components thereof, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, a lipoprotein, polyphosphazene, ISCOM matrix, ISCOPREP, DC-chol and DDBA. ### Claim 19 (depends on 15) The immunogenic composition of claim 15 wherein the host is a primate. ### Claim 20 (depends on 19) The immunogenic composition of claim 19 wherein the primate is a human. ### Claim 21 (depends on 14) The immunogenic composition of claim 14 which is substantially free from transferrin receptor proteins of said pathogen. ### Claim 22 (depends on 14) A method of generating an immune response in a host, comprising administering thereto an immuno-effective amount of the immunogenic composition of claim 14. ### Claim 23 (depends on 22) The method of claim 22 wherein the immune response is a humoral or a cell-mediated immune response. ### Claim 24 (depends on 23) The method of claim 23 wherein the immune response provides protection to the host against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight of between about 70,000 and about 90,000 daltons wherein said molecular weight is determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis or that produces a protein that induces antibodies in the host specifically reactive with the lactoferrin receptor protein. ### Claim 25 (depends on 14) A method for producing a vaccine, comprising: administering the immunogenic composition of claim 14 to a test host to determine an amount and a frequency of administration thereof to confer protection against disease caused by a bacterial pathogen that produces a lactoferrin receptor protein having a molecular weight of between about 70,000 and about 90,000 daltons wherein said molecular weight is determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis or a protein that induces antibodies in a host specifically reactive with the lactoferrin receptor protein; and formulating the immunogenic composition in a form suitable for administration to a treated host in accordance with said determined amount and frequency of administration. ### Claim 26 (depends on 25) The method of claim 25 wherein the treated host is a human.